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Abstract
Brain invasion by glioblastoma determines prognosis, recur-
rence, and lethality in patients, but no master factor coordi-
nating the invasive properties of glioblastoma has been iden-
tiﬁed. Here we report evidence favoring such a role for the
noncanonical WNT family member Wnt5a. We found the most
invasive gliomas to be characterized by Wnt5a overexpression,
which correlated with poor prognosis and also discriminated
inﬁltrating mesenchymal glioblastoma from poorly motile
proneural and classical glioblastoma. Indeed, Wnt5a overex-
pression associated with tumor-promoting stem-like charac-
teristics (TPC) in deﬁning the character of highly inﬁltrating
mesenchymal glioblastoma cells (Wnt5aHigh). Inhibiting
Wnt5a in mesenchymal glioblastoma TPC suppressed their
inﬁltrating capability. Conversely, enforcing high levels of
Wnt5a activated an inﬁltrative, mesenchymal-like program in
classical glioblastoma TPC and Wnt5aLow mesenchymal TPC.
In intracranial mouse xenograft models of glioblastoma, inhi-
biting Wnt5a activity blocked brain invasion and increased
host survival. Overall, our results highlight Wnt5a as a master
regulator of brain invasion, speciﬁcally TPC, and they provide
a therapeutic rationale to target it in patients with glioblas-
toma. Cancer Res; 77(4); 996–1007. 2016 AACR.
Introduction
To date, human grade IV gliomas (glioblastomas; hGBM) are
incurable tumors. Average survival barely exceeds 16months even
with the best andmost aggressive therapies (1, 2). In combination
with uncontrolled growth, the hGBM cells rapidly migrate and
spread throughout the brain tissue, thereby eluding surgical
ablation and radiotherapy. This deadly combination represents
a nearly insurmountable obstacle for the development of effective
therapies for high-grade gliomas (3, 4). Understanding of the key
mechanisms that are responsible for the inherent ability of hGBM
cells to migrate and invade the brain parenchyma is vital for the
identiﬁcation of new, more effective therapies.
Signiﬁcant progress has been made in unraveling the many
signaling moieties that elicit invasiveness in hGBM cells.
Numerous intertwined pathways, such as TGFb, Sonic Hedge-
hog, PI3K/Akt signaling, and epigenetic regulators enhance
cleavage of the extracellular matrix in the brain and foster
glioma cell invasion (5). Many of these pathways impinge on
common effectors, such as protease activation or degradation
of b-catenin (6, 7). The Notch and Wnt/b-catenin signaling
pathways can also activate an epithelial-to-mesenchymal–like
program in malignant gliomas, thereby modulating the motil-
ity of hGBM cells and their invasiveness (8).
These ﬁndings notwithstanding, the perspective existence,
identity, and functions of key master regulatory factors that, per
se, can globally drive the network of signaling pathways bestow-
ing the invasive phenotype upon hGBM cells remain undeter-
mined. The pleiotropic functions carried out by Wnt proteins in
neurogenesis and stem cell proliferation and differentiation
make members of this family good candidates for this role.
Deregulation of the Wnt signaling pathway is often associated
with the induction and progression of cancer in several tissues,
including the CNS (ref. 9; reviewed in refs. 10, 11). Various
members of the Wnt family can activate b-catenin–dependent
intracellular signaling (12). This occurs through the binding of
the canonical Wnts, such as Wnt1, Wnt3a, or Wnt7a, to speciﬁc
surface receptor complexes, which induces the stabilization of
cytoplasmic b-catenin and promotes its nuclear entry. Once in
the nucleus, b-catenin stimulates the transcription of target
genes, thus promoting predominantly glioma cell proliferation
via TCF/LEF family of transcription factors (13). If the Wnt/
b-catenin pathway is blocked, an antineoplastic response is
normally observed (14). Most notably, noncanonical Wnts
such as Wnt2, Wnt4, Wnt5a, Wnt6, and Wnt11 modulate
predominantly cell movement and polarity through the
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activation of b-catenin–independent pathways (15). Of impor-
tance, it appears that canonical and noncanonical Wnts, par-
ticularly Wnt3a and Wnt5a (16), may be somewhat intertwined
and can operate to antagonize one another (17).
Deregulation/upregulation ofWnt5a has been linked to cancer
invasion andmetastasis in some solid tumors (18–22), yet little is
known about its actual pathophysiological role in hGBMs. It has
been shown that Wnt5a is overexpressed in high-grade gliomas,
but the role forWnt5a in regulating proliferation andmigration in
gliomas has only been demonstrated, in a few cell lines, in vitro
(23–27). Here, we explore whether Wnt5a can function as a
master regulator of the invasive capacity of hGBMs. We demon-
strate that exacerbated Wnt5a expression is associated with, and
single handedly responsible for, the manifestation of an exacer-
bated functional and molecular invasive phenotype in glioma
cells, whereas its inhibition produces the opposite effects. Nota-
bly, this phenomenon occurs in tumor-promoting stem-like cells
(TPC; refs. 28–30), aka the cancer stem cell population. The effects
that we observed upon inhibition of Wnt5a in an intracranial
xenograft hGBM model suggest that this approach may have
notable, putative therapeutic implications for the cure of these
tumors.
Materials and Methods
Primary cell culture and culture propagation
hGBM, anaplastic, and low-grade gliomas tissue samples were
obtained in accordance with research ethics board approval from
the National Neurological Institute "C. Besta" (Prot. 02) and
classiﬁed according to theWorld HealthOrganization guidelines.
hGBMpatient–derived TPCswere isolated as previously described
(28, 31). Primary (acutely dissociated cells) or established TPCs
were plated inNeuroCult NS-Amedium (Stemcell Technologies),
containing 20 ng/mL of EGF (PeproTech) and 10 ng/mL of FGF2
(PeproTech; ref. 28). As reference, human neural stem cell (hNSC;
ref. 32) and the human glioma cell line U87MG were employed.
Cell line authenticity was last tested in January 2016 using CNV
proﬁling.
Immunoﬂuorescence and immunohistochemistry
Primary human samples were postﬁxed and processed, and
immunohistochemistry was performed on 10-mm-thick cryostat
sections as previously shown (28, 31, 33). Tissue sections were
stained according to manufacturer's instructions (see Supple-
mentary Methods). Cell nuclei were counterstained by DAPI
(Sigma-Aldrich). Negative controls were obtained by omitting
primary antibody. TPCs were seeded onto Cultrex (Trevigen)-
coated glass coverslips and staining was performed as described
earlier (28, 31, 33). Fluorescent images, n ¼ 5 ﬁelds/each
independent lines, were obtained using a Zeiss Axioplan2
Microscope and Leica DMIRE2 Confocal Microscope.
In vitro invasion assays
Invasion assays were performed in 6-well Transwell chambers
as shown (34). The upper side of the ﬁlters was coated with
Cultrex (Trevigen) and 2 105 cells were seeded onto the layer of
Cultrex in DMEM/F12 mitogen-free medium. Two weeks after
plating, cells on the upper side of the ﬁlters were mechanically
removed, and those migrated onto the lower side were ﬁxed and
stained by using the Hemacolor Rapid Staining Kit (Merck Milli-
pore). The number of cellsmigrated through the Cultrex layer was
scored by microscopy.
siRNAs, transfection, and quantifying gene silencing
siRNAs, transfection, and the quantiﬁcation of gene silencing
were performed according to manufacturer's instructions (see
Supplementary Methods).
Cell sorting analysis
For cell sorting analysis, 3  106 cells per sample were iden-
tiﬁed, electronically gated on forward and orthogonal light scatter
signals, sorted and analyzed withMoFlo XDP (Beckman Coulter)
and with Summit V5.2 software (Beckman Coulter). Events
representing cells binding anti-Wnt5a were identiﬁed by their
light scatter and ﬂuorescent signatures. Background ﬂuorescence
was estimated by substituting primary antibodies with speciﬁc
isotype controls. Autoﬂuorescence was also measured for each
condition tested.
RNA quantitation, microarray, and data analysis
Total RNA both from tissue samples and from cells was
extracted using the RNeasy Mini Kit (Qiagen). cDNA was synthe-
tized using SuperScript III (Invitrogen). Relative gene expression
was measured by real-time PCR as described (33), quantitative
PCR reactionswere run in duplicate and normalized toGAPDHas
endogenous control. Whole human brain tissue RNA (WHB,
Ambion, Invitrogen) orhNSCs employed as controls. RNAexpres-
sion proﬁling was performed using Affymetrix GeneChip Human
Transcriptome Array 2.0 (see Supplementary Methods). Raw
transcriptome data were deposited in the GEO repository (acces-
sion number: GSE76422). Expression data analysis was per-
formed using R and the Partek Genomics Suite package ver.
6.6. Low-level analysis and normalization were done using the
GCRMA R package of Bioconductor and Partek. Biologic function
and pathway analysis were conducted using Ingenuity Pathway
Analysis (IPA; Qiagen).
In vivo evaluation of tumorigenicity
Tumorigenicity was determined by injecting hGBM TPCs into
the right striatum of Scid/bg mice (Charles River Laboratory) as
described (28). All animal procedures were conducted in accor-
dance with the Guidelines for the Care and Use of Laboratory
Animals and approved by the ethics board of the University of
Milan Bicocca (Prot. 111). For assays of tumor initiation, 3 mL of a
1.5 104, 5 103, 2.5 103 ofWnt5a-puriﬁed cell fractions were
injected orthotopically. Mice were infused with co- and post-
treated paradigms as previously described (see Supplementary
Methods; ref. 28). Tumor formation and growth were indirectly
calculated once per week by sequential images taken with In Vivo
Lumina (Xenogen, Caliper Life Sciences) as described previously
(33, 35). Mice were sacriﬁced at different times comprised
between 4 and 12 weeks postinjection, according to the cell line
originally injected.
Analysis of dataset
We took advantage of the cBioPortal for Cancer Genomics
(http://www.cbioportal.org/faq.jsp) and the TCGA brain cancer
database (actually NIH GDC Legacy Archive: https://gdc-portal.
nci.nih.gov/legacy-archive) containing–omic data (transcription-
al, mutational, DNAmethylation, and CNV) of 617 patients with
glioblastoma. Data analysis depended on the availability of data
ﬁles and clinicopathologic information. Signiﬁcancewas assessed
both using web interfaces (GISTIC 2.0, cBioportal mutations
pipeline) and statistical tests (ANOVA, Wilcoxon).
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Figure 1.
Wnt5a expression correlates with grading and hGBM subtypes in patients' specimens and their TPCs. A, Higher Wnt5a mRNA levels as detected by
qPCR in anaplastic gliomas (AG; n ¼ 6) and hGBM (n ¼ 24) as compared with low-grade gliomas (LG; n ¼ 3) and with whole human brain (WHB).
 , P < 0.0001, Student t test. Among hGBMs, mesenchymal tissues (n ¼ 7) display signiﬁcantly higher Wnt5a expression versus classical (n ¼ 13)
and proneural subtypes (n ¼ 4).  , P < 0.0001;  , P ¼ 0.013, Student t test. B, Within the TCGA dataset, Wnt5a expression is signiﬁcantly
higher in the mesenchymal hGBM subtype (Mes; n ¼ 153) than in the classical (Cla; n ¼ 139; P < 0.001, Wilcoxon) rather than in the proneural
(Pro; n ¼ 97; P ¼ 0.6439, Wilcoxon). C, Expression levels of the genes associated with the Wnt-Ca2þ pathway in mesenchymal hGBM tissues versus
WHB, as determined by qPCR.  , P < 0.05;  , P < 0.01;  , P < 0.001, pooled variant t test. (Continued on the following page.)
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Statistical analysis
For in vitro studies, statistical tests were performed using
GraphPad Prism v5.0 software, and ANOVA or Student t test
according to the variance and distribution of data. Differential
gene expression from microarray data was assessed by the
implementation of the ANOVA test available in Partek Geno-
mic Suite 6.6 with Benjamini–Hochberg false discovery rate
(FDR) < 0.05. Because of the deviation from the normality
distribution assumption, raw gene expression values of both
cell lines and tissues were log2-transformed, beforehand. In vivo
survival curves were estimated using GraphPad Prism v5.0
software, using the Kaplan–Meier method, and the curves were
compared by log-rank test. In vivo comparisons between treated
and control mice were carried out with a hierarchical linear
model for repeated measurements as in (36). A 5% cutoff was
used to validate result signiﬁcance.
Results
Wnt5a overexpression in the most inﬁltrative high-grade
gliomas and their TPCs
In agreement with previous observations (23), quantitative
real-time analysis (qPCR) conﬁrmed Wnt5a overexpression in
the most inﬁltrative malignant glioma such as hGBMs and ana-
plastic gliomas but was not observed in low-grade gliomas (37)
when compared with normal tissues (Fig. 1A and Supplementary
Table S1). When dissecting the hGBM expression proﬁles further,
Wnt5amRNA levels can be used to categorize hGBMs tissues into
the known subgroups (Fig. 1A and Supplementary Fig. S1A;
ref. 38), even though there was no signiﬁcant correlation with
copy number alterations (Supplementary Table S2). These data
were conﬁrmedby analysis of public datasets (Supplementary Fig.
S1B andS1CandCancerGenomeAtlas, TCGA, ResearchNetwork,
2013, data). Furthermore, in the TCGA dataset, signiﬁcant Wnt5a
overexpression was found in the mesenchymal subtype as com-
pared with the classical one (Fig. 1B). This overexpression did not
correlate with differences in the methylation proﬁles of the
WNT5A gene (Supplementary Fig. S1D). Across independent
datasets, Wnt5a was also a predictor of poor prognosis (Supple-
mentary Fig. S1E). Strikingly, the expression levels of the genes
associated with the Wnt-Ca2þ signaling pathway were higher in
tissues from mesenchymal hGBMs, which are endowed with
higher aggressiveness and invasiveness (38–40) as comparedwith
healthy brain tissues (Fig. 1C).
These results were further conﬁrmed when monitoring protein
expression. Experiments that assessed Wnt5a immunostaining in
malignant and low-grade glioma specimens reiterated that high
Wnt5a expression was associated with the most inﬁltrative glio-
mas (Fig. 1D). Intense and widespread Wnt5a immunolabeling
was retrieved in many cells of mesenchymal hGBM tissues as
compared with few positive cells in the proneural and classical
ones (Fig. 1D).
The same pattern of elevated Wnt5a expression observed in
tissues derived from different hGBM subgroups was identiﬁed
in their TPCs. Thus, TPCs from the mesenchymal subcluster
had the highest expression of Wnt5a protein and mRNA as
compared with cells from classical and proneural hGBMs
(Fig. 1E–G; refs. 41–43). In contrast, the classical TPCs type
predominantly expressed canonical Wnt3a (Supplementary
Fig. S1F).
Wnt5a drives the phenotypic change of cancer stem cells to high
inﬁltrative potential
To determine whether Wnt5a exerts its biologic actions on
the TPC population and to deﬁne the nature of such effects, we
assessed the invasive capacity of TPCs from different hGBM
subsets on Matrigel-coated membranes, in vitro. As expected,
mesenchymal TPCs invaded much more efﬁciently than those
from classical and proneural lineages (Fig. 2A and B). The
invasive potential was Wnt5a-dependent, as inhibition of
Wnt5a signaling by a Wnt5a blocking antibody (W5a-Ab;
ref. 44), by an endogenous Wnt5a antagonist (the secreted
frizzled-related protein 1, SFRP1), or by siRNA-mediated
WNT5A silencing reduced hGBM TPCs migration through the
Transwell (2-fold reduction in invasive cells; Fig. 2A–D, Sup-
plementary Fig. S2A, S2B, S2E and data not shown). Interest-
ingly, the different invasive potential among the different TPCs
subclusters was inversely correlated to their inherent rate of
ampliﬁcation in vitro, in agreement with the "grow or go"
model (Fig. 2E; ref. 45).
Notably, Wnt5a alone could modify the overall hGBM TPCs
intrinsic invasive phenotype. In fact, when less inﬁltrating
classical TPCs were treated with an exogenous recombinant
human Wnt5a protein (rhWnt5a) or when stable WNT5A
overexpression was induced, an exacerbated invasive pheno-
type was acquired. Thus, not only did the in vitro migratory
capability increase to levels that far exceeded that of their empty
vector-infected siblings but also these modiﬁed cells exhibited
the invasive potential that is normally observed in na€ve mes-
enchymal TPCs (Fig. 2F and G). Similar results were observed
when proneural hGBM TPCs were treated with rhWnt5a or
when stable WNT5A overexpression was induced (Supplemen-
tary Fig. S2C and S2D). Most important, the acquisition of
exacerbated invasiveness in classical hGBM cells upon these
treatments was associated to the acquisition of a "highly
migratory" gene expression signature (Fig. 2H and Supplemen-
tary Table S3).
Altogether, these ﬁndings demonstrate that activation of the
noncanonical Wnt5a pathway drives inﬁltrative potential in
hGBM TPCs. More importantly, Wnt5a stimulation alone can
trigger a global phenotypic switch in those hGBM TPCs that
inherently possess a limited invasive ability. Upon Wnt5a stim-
ulation, these TPCs acquire novel functional and molecular
phenotypes, typical of the most inﬁltrative mesenchymal TPCs.
(Continued.) D, Immunolabeling of surgery specimens showing intense Wnt5a immunoreactivity (green) in hGBM (GBM#23) and anaplastic astrocytoma
(AA#8) tissues as compared with few Wnt5a immunoreactive cells in low-grade samples (LG#4 and LG#5; top). Bottom, confocal immunolabeling
showing that mesenchymal hGBM tissues (GBM#22 and GBM#20) display much more intense and widespread Wnt5a immunoreactivity versus
classical (GBM#14) and proneural (GBM#18) ones. E, Higher Wnt5a expression in mesenchymal hGBM TPCs (n ¼ 5), as detected by qPCR, versus
classical (n ¼ 6) and proneural (n ¼ 7) TPCs.  , P < 0.0001, Student t test. F, Strong immunolabeling for Wnt5a in mesenchymal TPCs (TPCs#22 and #20)
as compared with weaker and infrequent signal in classical (TPCs#26 and #34) and proneural (TPCs#29 and #18) lines. G, Quantiﬁcation of Wnt5a
expression shown in F.  , P < 0.0001 versus classical;  , P ¼ 0.0003 versus proneural TPCs, 2-tailed c2 test with continuity correction. Scale bar
in D, F, 50 mm. Insets, no primary antibody as control. A, C, E, G, mean  SEM from at least three independent experiments.
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Figure 2.
Wnt5a overexpression drives invasive ability in hGBM TPCs. A, In vitro invasion assay showing that mesenchymal TPCs migrate more efﬁciently than
proneural and classical lines (top to bottom, left). Cells were seeded in mitogen-free medium onto the upper side of the ﬁlters coated with Cultrex and
the number of cells migrated through the Cultrex scored after 2 weeks. By administration of Wnt5a-blocking antibody (W5a-Ab, 2 mg/mL; middle),
the migration of all three kinds of TPCs is lessened. B, Quantiﬁcation of TPCs migration shown in A, Student t test.  , P < 0.0001 versus mesenchymal and
classical;  , P ¼ 0.023 versus proneural control TPCs. C, TPC migration decrease is concomitant with siRNA-mediated Wnt5a downregulation.
Quantiﬁcation is shown in D.  , P ¼ 0.001; , P < 0.0001, one-way ANOVA. E, Differences in the growth kinetics were detected among classical,
mesenchymal, and proneural TPCs, with the former characterized by fast growth rate and the latter comprising slowly diving TPCs. F, Treating TPCs
with rhWnt5a or inducing stable Wnt5a overexpression (LV-Wnt5a) enhances the migration of classical TPCs (#26) versus Control-Fc or empty
vector–infected siblings. Quantiﬁcation is shown in G.  , P < 0.0001, Student t test. H, Ingenuity analysis reporting a "highly migratory" functional signature
acquired by classical TPCs after stable Wnt5a overexpression. Bars are colored in shades of orange according to the different level of signiﬁcance. Scale
bar in A, C, F, 100 mm. Scale bar in insets (higher magniﬁcation), 50 mm. B, D, G, mean  SEM from at least three independent experiments.
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These ﬁndings indicate that WNT5A may function as a master
switch gene for inﬁltration.
Wnt5a: an "apical" master role in the molecular regulatory
network sustaining inﬁltration capacity in hGBMs
To determine whether a cogent correlation exists between
increased Wnt5a levels and enhanced invasion, we sorted mes-
enchymal TPCs into 2 distinct populations expressing either high
(Wnt5aHigh) or low Wnt5a levels (Wnt5aLow; Fig. 3A). In vitro
migration assays showed that Wnt5aHigh TPCs invaded more
efﬁciently than their Wnt5aLow counterpart (2-fold increase in
invasive cells; Fig. 3B and C). Most importantly, the exposure of
Wnt5aLow mesenchymal TPCs to rhWnt5a modiﬁed their pheno-
type to match that of their most inﬁltrative Wnt5aHigh counter-
parts (Fig. 3D). Thiswas also in agreementwith experiments using
glioma cells, whose invasive capacity was inherently nil, such as
the U87 cell line. Forcing the overexpression of WNT5A was
sufﬁcient to bring about the expression an exacerbated inﬁltrative
capacity (and an "inﬁltration-congruent" molecular signature)
not only in vitro but also in vivo (Supplementary Fig. S3 and
Table S4).
Next, we examined the transcription proﬁles of Wnt5aHigh
and Wnt5aLow populations derived from mesenchymal hGBM
tissues (Fig. 3E and F). Differential analysis of the transcrip-
tional proﬁles demonstrated that the Wnt5aHigh population
expressed a distinctive inﬁltrative molecular program not
observed in the Wnt5aLow pool. In fact, the transcriptional
modules of these 2 fractions were strikingly opposed when
analyzing genes that control cell movement, homing, migra-
tion, and invasion (Fig. 3G and H and Supplementary
Table S5). Also, most differentially expressed genes concerned
pathways related to cell movement, migration, and invasion
(Supplementary Fig. S4). Altogether, these data suggested that
the key molecular properties that deﬁne the "inﬁltrative sig-
nature" in mesenchymal hGBM cells are restricted to the
Wnt5aHigh cell population.
In summary, these ﬁndings demonstrate that activation of
the noncanonical Wnt5a pathway drives tissue migration and
inﬁltration by hGBM TPCs. Strikingly, Wnt5a stimulation
alone can trigger a global phenotypic switch in those hGBM
TPCs that inherently possess limited invasive capacity. Upon
stimulation of Wnt5a, these TPCs acquire both new molecular
and functional phenotypes that are representative of the most
inﬁltrative Wnt5aHigh mesenchymal TPCs.
The Wnt5a-driven transition of TPCs to a highly inﬁltratory
phenotype exacerbates their ability to invade the brain
parenchyma
To reinforce the correlation between Wnt5a enhanced levels
and the actual hGBM TPCs invasion ability in the brain paren-
chyma in vivo studies were performed. In agreement with our
ﬁndings above, the xenografting of mesenchymal TPCs did
establish intracranial hGBMs with a faster and broader inﬁl-
tration pattern than those generated by classical or proneural
TPCs (Fig. 4A). Mesenchymal hGBMs had cells that quickly
spread from the graft site and dispersed extensively throughout
the grey and white matter. In addition, the migratory cell
population rapidly colonized the proximal brain hemisphere
migrating along the ﬁbers of the corpus callosum, the anterior
commissure, and internal capsule (Fig. 4A and Supplementary
Fig. S5A). The heightened invasive potential was tightly asso-
ciated with the Wnt5aHigh mesenchymal TPCs pool (Fig. 4B). In
contrast, the mesenchymal Wnt5aLow TPCs gave rise to larger,
yet more deﬁned neoplastic masses that remained localized to
the ipsilateral hemisphere, reminiscent of hGBM xenografts
derived from classical TPCs (Fig. 4B). When classical TPCs were
transduced with a WNT5A expression vector, in line with their
"molecular ﬁngerprint" (Fig. 2H), they exhibited an unusual
migration, which was active along the ﬁbers of the corpus
callosum with an enhanced lateral spread within the paren-
chyma, a result that was comparable to that of mesenchymal
TPCs (Fig. 4C). Furthermore, the highly invasive cells that
reached the contralateral hemisphere in our TPC-established
xenografts retained their inherent TPC characteristics. In fact,
upon their isolation from the controlateral hemisphere, cells
preserved the functional and molecular stem-like properties
of the original mesenchymal or classical TPCs used to estab-
lish the xenograft in ipsilateral striatum (Supplementary
Fig. S5B and S5C). Notably "contralateral" TPC neurospheres
could be isolated from mesenchymal TPC-induced tumors
signiﬁcantly earlier than in tumors from classical ones—3 and
30 days posttransplant, respectively. These ﬁndings clearly
demonstrate that Wnt5a drives TPCs invasiveness in an in vivo
setting and can trigger a phenotypic state transition of the
less inﬁltrating TPCs (Wnt5aLow TPCs), to the most aggressive,
invasive phenotype.
Inhibition of Wnt5a hinders brain parenchyma inﬁltration by
hGBMs
The ﬁndings above strongly point to the hypothesis thatWnt5a
may be a powerful therapeutic target for hGBM to further brain
invasion by glioma cells.
We assessed this hypothesis by inhibiting Wnt5a activity in
hGBM xenografts in an intracranial preclinical model. Immedi-
ately after orthotopic implantation of mesenchymal hGBM TPCs
into immunodeﬁcient Scid mice (28, 46), Wnt5a activity was
antagonized for 2weeks by the intraparenchymal infusion (33) of
either W5a-Ab or a Wnt5a-derived hexapeptide (PepA), both
capable of inhibiting Wnt5a-induced protein kinase C and Ca2þ
signaling (47). Both treatments signiﬁcantly decreased the size of
the mesenchymal TPC–derived, intracranial hGBMs as compared
with control animals (Fig. 5A). Remarkably, 9 weeks following
transplantation and 7 weeks after the cessation of inhibitor
infusion, the tumors receiving W5a-Ab or PepA were still signif-
icantly less spread as compared with controls. Furthermore,
12 weeks after infusion had ceased, intracranial invasion
remained considerably reduced, which also resulted in signiﬁ-
cantly increased survival. Kaplan–Meier analysis revealed amedi-
an survival of 175 and 173 days for mice receiving W5a-Ab and
PepA, respectively, versus 134 days for controls (Fig. 5B), con-
ﬁrming the therapeutic efﬁcacy of W5a-Ab and PepA administra-
tion. Interestingly, these effects were not restricted to the mesen-
chymal hGBMs. To a lesser extent than for xenografts derived from
themesenchymal cluster, classical TPC-derivedhGBMsdopossess
the capacity to inﬁltrate, which is of cogent clinical relevance. The
spreading of xenograft tumors established from classical hGBM
TPCs was also signiﬁcantly reduced when treated with intrapar-
enchymal infusion of either W5a-Ab or PepA (Fig. 5C). This
reduction in migratory ability was even more apparent when
classical TPCs were allowed to establish sizeable tumors (33)
prior to the infusion of PepA orW5a-Ab (Fig. 5D; ref. 33). Similar
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Figure 3.
ElevatedWnt5a levels in brain tumor cells correlatewith activationof functional andmolecular programs that underpin invasivepotential.A,Mesenchymal TPCswere
gated and sorted according to Wnt5a expression. B, When treated with exogenous rhWnt5a, Wnt5aLow cells acquire an unprecedented ability to migrate,
quantitatively matching that of Wnt5aHigh siblings. Quantiﬁcation of this phenomenon is shown in C, mean  SEM.  , P < 0.0001, Student t test. D, Phase-bright
microphotographs of neurospheres showing that Wnt5aLow cells display typical rounded morphology as compared with more heterogeneous cell populations
in both Wnt5aHigh and rhWnt5a-treated Wnt5aLow cultures, characterized by many protruding bipolar cells (red arrowheads), indicative of enhanced cell
adhesion and migration. E and F, Example of mesenchymal hGBM specimen (GBM#20) immunostained for Wnt5a (E), gated and sorted according to Wnt5a
expression (F). G, IPA shows that most overactivated cellular functions in the Wnt5aHigh population belong to cell movement and migration (orange), unlike the
Wnt5aLow pool. The latter is characterized by enrichment in cell apoptosis, proliferation, and differentiation functions (blue). The higher the statistical signiﬁcance,
the bigger the rectangles. H, When compared with Wnt5aLow siblings, genes upregulated in Wnt5aHigh cells are mostly related to biological functions as cell
movement, homing, and migration (left). Red and blue bars count for up- and downregulated genes, respectively. Right, even by comparing Wnt5aHigh and
Wnt5aLow fractions with the unsorted, original population, the overrepresented genes and their biological functions in the Wnt5aHigh pool were mostly
associated with cell movement, migration, and invasion. The positive z-scores mean functional activation. Scale bar in B, D, 100 mm. Insets, higher magniﬁcation.
Scale bar, 50 mm.
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results were observed in xenografts from proneural hGBM TPCs
(Fig. 5E and F).
Discussion
In this work, we demonstrate that it is the level of expression of
Wnt5a that deﬁnes the inﬁltrative capacity of human glioma cells
and that, by itself, Wnt5a bestows an exacerbated invasive phe-
notype upon these cells by activation of a complement of func-
tional and molecular characteristics. One of the most prominent
cell targets of exacerbated Wnt5a activity is the tumor-initiating
glioma TPC pool. By antagonizing Wnt5a activity in this cell
population, the invasive potential is vastly reduced. These ﬁnd-
ings suggest that signiﬁcant, therapeutic beneﬁcial effects can be
gleaned for intracranial hGBM.
The expression ofWnt5a is known to be upregulated in human
gliomas (23). Findings on Wnt5a roles and functions in these
tumors are restricted to the observed increased motility in cul-
tured cell lines (25, 27). Recently, however, it has been shown that
the enhanced migration caused in hGBMs by reduced Wnt inhib-
itor 1 activity is mediated by Wnt5a (48). We now demonstrated
that Wnt5a functions as a master regulator in determining the
prototypical invasive glioma potential in hGBMs, particularly, in
their TPCs.
First, we show that Wnt5a overexpression is, in fact, a
deﬁning feature of the most inﬁltrating malignant gliomas,
that is, anaplastic gliomas and hGBMs (23). In the latter, not
only are the highest Wnt5a levels found in the mesenchymal
phenotype—which has been associated with tumor aggres-
siveness and elevated invasive potential (38–40, 49)—but
Wnt5a expression can even be used to categorize hGBMs tissues
into the known subgroups (38). Second, the strong tie between
invasiveness and Wnt5a overexpression is directly connected
with cancer stem–like hGBM TPCs. Wnt5a expression was
found to be from 10- to 1,000-fold higher in mesenchymal
hGBM TPCs when compared with TPCs derived from the
Figure 4.
Wnt5a levels inﬂuence dispersal of hGBM TPCs in vivo. A, Serial histologic reconstruction shows that at 8 weeks following implantation, luciferase-tagged
mesenchymal TPCs (luc-TPCs; left, TPCs#22) form smaller tumor masses but display a broader invasion pattern as compared with classical (middle,
TPCs#26) and proneural TPCs (right, TPCs#29). n ¼ 5 mice per groups. Scale bar, 1 mm. B, Brain sections showing that the Wnt5aHigh TPC pool is the
most invasive since, in only 12 weeks following implantation, as few as 1.5  104 cells established tumors (top, left) as extended as those established by
20 fold more (3  105) unsorted mesenchymal TPCs (TPCs#22; top, right). When implanting 1.5  104 Wnt5aLow mesenchymal TPCs (bottom, left),
more compact masses were generated, resembling classical TPCs (compare with A, middle). n ¼ 5 mice per groups. Scale bar, 1 mm. Insets, higher
magniﬁcation. Scale bar, 50 mm. Bottom right, Kaplan–Meier survival curves demonstrating that mice receiving 1.5  104, 5  103, or 2.5  103 Wnt5aHigh TPCs
die earlier than those implanted with similar amounts of Wnt5aLow cells, Mantel–Cox and Breslow–Wilcoxon tests, log-rank P < 0.0001, n ¼ 5 mice per
groups. C, When classical TPCs (TPCs#26-empty; left) were forced to overexpress Wnt5a (TPCs#26-Wnt5a; right), in 4 and 6 weeks established
tumors whose spreading was signiﬁcantly enhanced, migrated along the ﬁbers of the corpus callosum much faster than those generated by empty
vector–infected cells (red arrowheads). Scale bars, 500 mm and 1 mm.
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Figure 5.
In vivo inhibition of Wnt5a activity impairs brain invasion. A, hGBM xenografts from mesenchymal luc-TPCs infused with either W5a-Ab or PepA display
reduced tumor growth as compared with controls, as shown by quantitative time course imaging analysis,  , P < 0.05;  , P < 0.01 versus control
hierarchical linear model for repeated measures; n ¼ 5 mice per groups. B, Brain sections from experiment A show that the tumors infused with W5a-Ab
and PepA spread signiﬁcantly less than controls. Bottom right, Kaplan–Meier plot of overall survival showing that mice treated with Wnt5a inhibitors
survived signiﬁcantly longer than controls, Mantel–Cox and Breslow–Wilcoxon tests, log-rank Wnt5a-Ab P ¼ 0.0006, PepA P ¼ 0.025 versus control;
n ¼ 5 mice per groups. Scale bar, 1 mm. C, While W5a-Ab was ineffective, PepA limited the growth of tumors established by classical TPCs as compared
with control (top).  , P < 0.001 hierarchical linear model for repeated measures; n ¼ 4 mice per groups. Bottom, Serial histological reconstruction
showed that W5a-Ab or PepA infusion reduced the spread of classical luc-TPC versus control (25 days posttransplantation; DPT), although the effect
of W5a-Ab was less intense. CC, corpus callosum; LV, lateral ventricle; St, striatum. Scale bar, 500 mm. D, By infusing either W5a-Ab or PepA with the
posttreatment regimen, signal from classical-luc TPCs was signiﬁcantly reduced versus control tumors.  , P < 0.01, hierarchical linear model for repeated
measures. n ¼ 4 mice per groups. E, By implanting proneural luc-TPCs, the overall F-luc signal intensity using either W5a-Ab or PepA was not reduced.
ns, nonsigniﬁcant; n ¼ 4 mice per groups. F, Immunohistochemical reconstruction revealed that spreading of tumors established by proneural TPCs was
inhibited by Wnt5a-Ab or PepA versus control tumors (41 DPT). Scale bar, 1 mm. A, C, D, E, mean  SEM; arrows mark the starting point of infusion.
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proneural and classical clusters—a reversed pattern as com-
pared with that of the Wnt5a antagonist Wnt3a (16). In
addition, the mesenchymal Wnt5aHigh TPC fraction, but not
its Wnt5aLow counterpart, displayed considerable invasive
capability, in vitro and in vivo. Finally, a direct correlation was
observed between Wnt5a levels and the invasive potential,
which demonstrated that Wnt5a overexpression is a driving
factor behind glioma TPCs inﬁltrative ability as a whole. In fact,
the observed difference between Wnt5aHigh and Wnt5aLow TPCs
in their ability to migrate could be abolished when the Wnt5a
pathway was activated in Wnt5aLow cells (Figs. 3B and C
and 4B). As expected, the very opposite phenomenon took
place when Wnt5a activity was antagonized in TPCs from all
hGBM subgroups, resulting in the ablation of their migratory
ability (Figs. 2A–D and 5). These ﬁndings clearly demonstrate
that diverse Wnt5a expression levels can confer distinct inher-
ent invasive ability to the different hGBMs and their TPCs.
A major discovery in this work was the fact that Wnt5a drives
acquisition of the glioma TPCs' exacerbated inﬁltrating pheno-
type by globally overhauling the inﬁltrativemolecular programof
these cells. It has been demonstrated previously that the invasive
behavior exhibited by glioma cells hinges on the coordinated
activation of multiple cell signaling pathways (3, 5, 50). For the
most aggressive TPC cells, that is, those of the mesenchymal
hGBM cluster, this translates into a speciﬁc signature in which
cellmotility,migration, and aggressiveness pathways are enriched
(39, 40, 49). Our analysis identiﬁed this molecular module in
highly invasiveWnt5aHighmesenchymal TPCs but not in their less
inﬁltrating Wnt5aLow siblings.
Neither mesenchymal Wnt5aLow, nor classical TPCs expressed
genes that gave rise to an "invasive" signature. Yet, whenWNT5A
levels were increased in both these TPCs, not only was invasive-
ness enhanced to the level of their counterparts but also its
expression concomitantly triggered the acquisition of an overall
expression proﬁle that matched the prototypical "inﬁltrative
signature" of mesenchymal hGBM, particularly their Wnt5aHigh
TPCs. Such a strong association between high Wnt5a levels and
the concomitant expression of both exacerbated inﬁltrating func-
tional and molecular characteristics in TPCs demonstrates that
Wnt5a is a key determinant of the invasive phenotype in hGBMs,
particularly in their stem-like TPCs. This is consistent with the
Wnt5a role as a membrane receptor ligand, which places it at an
apical, hierarchic position in the ramiﬁed network of molecular
pathways that underlies brain cancer cell inﬁltration. While our
ﬁndings show that the overexpression of Wnt5a is particularly
prominent in the hGBM subcluster the Wnt5a effects on glioma
cell inﬁltration are to be seen as a general phenomenon, which
takes place in all hGBM tumors.
The fact that Wnt5a overexpression might be associated to
distinct degrees of invasiveness in various hGBM subtypes and
their associated TPCs points to the existence of heterogeneous
subpopulations of hGBM tumor–founding stem-like cells
endowed with inherently different inﬁltration capacities in
these high-grade gliomas. This is demonstrated by the co-
existence of Wnt5High and Wnt5aLow TPC pools inside the very
same mesenchymal hGBM specimen that display dissimilar
inﬁltrative ﬁngerprints and capacities. Thus, the axiomatic
heterogeneity that characterizes hGBMs at the cytohistologic
level may extend to encompass disparateness in the intrinsic
inﬁltrating capacity of these cancers' very founder cells. Of
paramount importance is the observation that the differential
ability to invade is interconvertible and that the switch
from a state to another can be accomplished, at both the
functional and molecular levels, by simply manipulating
Wnt5a levels in hGBM TPCs. A schematic that incorporates
the above ﬁndings portrays a tentative model of how invasion
may be regulated at the TPC level in hGBM is shown in
Supplementary Fig. S6.
Also, of note is the observation that the fast inﬁltrating hGBM
cells, that reach the hemispheres contralateral to the transplan-
tation site in our orthotopic model, retain the prototypical fea-
tures of stem-like TPCs of mesenchymal and classical clusters
(Supplementary Fig. S5B and S5C). This reinforces the notion that
properties of tumor-initiating cells actively support the lethal
invasive process in hGBMs.
The critical, master role played by Wnt5a in regulating hGBM
TPC physiology—the promotion of an inﬁltratory cell func-
tionality and the initiation of the global invasive molecular
expression signature—makes Wnt5a a promising target for
therapeutic approaches that may antagonize the spreading of
tumor-initiating cells throughout the brain. When Wnt5a activ-
ity was attenuated in preclinical experimental conditions using
orthotopic hGBM xenografts, the ability of the tumor mass to
expand and migrate was signiﬁcantly reduced. The peptide
treatment was more effective, likely due to the ability of the
small molecules to diffuse into the tissue much more efﬁciently
than the larger antibody molecules. As expected, the beneﬁcial
effects were less evident in grafts established by the classical and
proneural hGBM cells and most prominent in those arising
from the most invasive mesenchymal TPCs.
Thus, anti-Wnt5a treatments have the potential to effectively
prevent invasion of the brain parenchyma by hGBM cells, par-
ticularly TPCs, endowed with the ability to establish or re-estab-
lish the whole tumor at the single-cell level at a new site. As these
experiments were conducted under preclinical conditions, these
ﬁndings will be more rapidly applied in support of clinical trials
and thus to the therapeutic setting. The availability of these
approaches might pave the way to future, more efﬁcacious com-
binatorial treatments, that combine approaches aimed at killing
the cancerous cells or to hinder their proliferation with strategies
that, simultaneously, limit the spreading of the tumor-initiating
cells.
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Correction
Correction: Wnt5a Drives an Invasive
Phenotype in Human Glioblastoma Stem-like
Cells
In this article (Cancer Res 2017;77:996–1007), which appeared in the February 15,
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Therapies, Italy; Department of Biotechnology and Biosciences, University of Milan
Bicocca, Milan, Italy; IRCSS Casa Sollievo della Sofferenza, c/o Instituto Mendel,
Rome, Italy; and Hyperstem SA, Lugano, Switzerland.
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